Ju-Lu Huang, NP
Nurse Practitioner · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Ju-Lu Huang’s office at (650) 988-8338 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$38,348
Medicare paid this office $38,348 for 146 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $14,301 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 108 | $12,802 | $114 |
| Advance care planning, first 30 minutes | 68 | $4,596 | $50 |
| Advance care planning, each additional 30 minutes | 53 | $3,447 | $47 |
| Long return visit (40+ min) | 17 | $1,884 | $111 |
Who their Medicare patients are
146 Original Medicare patients in 2024. Average age 81 · 85 and older 40% · Women 52% · Also on Medicaid 36% · Health risk score 2.77. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 54% · Atrial fibrillation 50% · Heart failure 47% · Chronic kidney disease 47% · Dementia 43% · Diabetes 40% · COPD 38% · Depression 32% · Stroke 30% · Cancer 29%.
The office billed $93,449, Medicare allowed $48,670 and paid $38,348; for 490 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Money from drug and device companies
$538 in 2025
| 2025 | 8 | 13 | None | $538 |
| 2024 | 2 | 2 | None | $138 |
| 2023 | 27 | 46 | None | $1,136 |
| 2022 | 1 | 2 | None | $41 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $139 | 5 payments
|
| Myriad Genetic Laboratories | Precisetumor | $126 | 1 payment
|
| Vertex Pharmaceuticals | Journavx | $125 | 1 payment
|
| Abbvie | Imbruvica | $42 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $30 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $29 | 1 payment
|
See all 13 published payments
| Daiichi Sankyo | Meals · 2025-11-20 | Datroway | $29 |
| Vertex Pharmaceuticals | Meals · 2025-11-19 | Journavx | $125 |
| Daiichi Sankyo | Meals · 2025-10-28 | Datroway | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-18 | Enhertu | $29 |
| Daiichi Sankyo | Meals · 2025-05-15 | Enhertu | $25 |
| Abbvie | Meals · 2025-05-07 | Imbruvica | $27 |
| Abbvie | Meals · 2025-04-22 | Imbruvica | $15 |
| Myriad Genetic Laboratories | Meals · 2025-04-03 | Precisetumor | $126 |
| Daiichi Sankyo | Meals · 2025-04-02 | Enhertu | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-27 | Opdivo | $19 |
| Karyopharm Therapeutics | Meals · 2025-03-13 | Xpovio | $29 |
| Daiichi Sankyo | Meals · 2025-02-14 | Enhertu | $26 |
| Merck Sharp & Dohme | Meals · 2025-01-10 | Keytruda | $30 |
See earlier years (2024, 2023, 2022)
2024: $138
| Abbvie | Epkinly | $125 | 1 payment
|
| Novartis Pharmaceuticals | Pluvicto | $13 | 1 payment
|
2023: $1,136
| Merck Sharp & Dohme | Keytruda | $118 | 5 payments
|
| Kite Pharma | Yescarta | $99 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $89 | 4 payments
|
| Janssen Biotech | Erleada | $87 | 4 payments
|
| Sobi | Doptelet | $69 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $59 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $52 | 3 payments
|
| Eisai | Lenvima | $51 | 2 payments
|
| Pfizer | Oxbryta | $48 | 3 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $40 | 2 payments
|
| Lilly USA | Verzenio | $32 | 1 payment
|
| Stemline Therapeutics | Orserdu | $32 | 1 payment
|
| GlaxoSmithKline | Zejula | $29 | 1 payment
|
| Daiichi Sankyo | Enhertu | $29 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $28 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $27 | 1 payment
|
| Astellas Pharma US | None | $27 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $25 | 1 payment
|
| MorphoSys US | Monjuvi | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $24 | 1 payment
|
| Genzyme | Enjaymo | $24 | 1 payment
|
| Seagen | Tukysa | $24 | 1 payment
|
| Celgene | Pomalyst | $23 | 1 payment
|
| Incyte | Monjuvi | $22 | 1 payment
|
| PharmaEssentia USA | Besremi | $20 | 1 payment
|
| Coherus Biosciences | Udenyca | $19 | 1 payment
|
| Secura Bio | Copiktra | $17 | 1 payment
|
2022: $41
| Taiho Oncology | Lonsurf | $41 | 2 payments
|
Professional record
- NPI
- 1174229181
- Licence
- CA 95024105
- Trained
- Yale University School of Medicine, 1997
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 3113 Middlefield Ave, Fremont, CA, 94539
- NPI first listed
- 2023-02-01
- NPI last updated
- 2023-02-01
- NPI record certified
- 2023-02-01
This is when the NPI record was last certified, not a medical board exam.